Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advexin in Recurrent Head and Neck Cancer
NCT00003257Phase 2Unknown
- Sponsor
- Sanofi
- Start
- Jan 1998
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad5CMV-p53 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sanofi. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
Ad5CMV-p53
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00003257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003257.